CHMP gives positive opinion recommending authorisation to GSK’s CKD drug
Chronic kidney disease affects roughly 700 million patients worldwide
Read More
Tag: daprodustat
GSK’s anaemia drug gets FDA advisory committee support for patients on dialysis
A final decision for daprodustat by the FDA is expected by 1 February 2023
Read More
GSK kicks off Phase III programme for daprodustat
GlaxoSmithKline has begun Phase III development of daprodustat, testing its potential as a treatment for anaemia associated with chronic kidney disease (CKD).
Read More
- SolasCure trial shows faster healing with Aurase Wound Gel
- Gilead data show investigational HIV combination maintains viral suppression
- Verdiva Bio completes enrolment for phase 2b study of oral GLP‑1 candidate VRB‑101
- MHRA approves imlunestrant tosylate as new breast cancer treatment
- ACD440 granted orphan drug status in the EU
